Mode
Text Size
Log in / Sign up
Phase 2 N=60 Randomized Triple-blind Treatment

Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain

Pain, Fracture, Sprain

Enrolled (actual)
60
Serious AEs
0.0%
Results posted
Feb 2017
Primary outcome: Primary: Time to Analgesia — 10; 35 minutes

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Fentanyl (Drug); Lansoprazole (Drug); Oxycodone (Drug)
Age
Adult · 18+ yrs
Sex
All
Sponsor
Massachusetts General Hospital
Primary completion
Feb 2009

Outcome Measures

OutcomeResultp-value
PRIMARY
Time to Analgesia
10; 35
PRIMARY
Pain Reduction
30; 24
SECONDARY
Occurrence of Untoward Opioid Side Effects
0; 1

Summary

Assess whether transbuccal fentanyl provides more rapid relief of orthopedic pain, than does the comparator Percocet

Eligibility Criteria

INCLUSION:

  • 18-60 years of age
  • Present to ED with a chief complaint of extremity injury
  • Negative pregnancy test (urine or blood)
  • Clinician judges subject to need extremity radiography to rule out a fracture
  • Subjects must indicate that their pain is of sufficient severity to warrant treatment with a pain medication stronger than acetaminophen or aspirin.
  • Subject's treating ED provider is aware of, and approves, participation (i.e. participation cannot be allowed to impair provision of standard patient care).

EXCLUSION:

  • Treating provider judges that IV analgesia is required
  • Allergy to acetaminophen or to any opiate/opioid
  • Currently taking phenothiazines or CNS depressants (including alcohol), or if subject has taken MAO inhibitors or SSRIs within the past two weeks
  • Already taken or been administered opioid analgesia for their current injury
  • Chronic opioid therapy or if the subject (or their medical records) indicate a history of opioid abuse
  • Breastfeeding mothers
  • If subject is planning to drive home after their ED visit, or if they are judged for any other reason to be non-candidates for opioid therapy.
  • hypersensitivity to lansoprazole
  • phenylketonuria
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00685295). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search